The annual meeting organised by EuropaBio, the European association representing the biotech sector, focused on discussions on the best ways to defragment and accelerate biomanufacturing in the EU, Biomanufacturing policies from other global regions were also addresses. Different policy files are underway at EU level, with an impact on relevant products or processes including biopharmaceuticals, new genomic techniques, detergents, alternative proteins and cell-cultivation .

This Summit report summarises the Strengths, Weaknesses, Opportunities and Threats (SWOT) analysis for biomanufacturing in Europe built on outcomes of the discussions. Among them, according to EuropaBio there is the urgent need to address the question “What does the EU want to be?”. The answer should include considerations on innovation, skills, smart and agile legislation and financial instruments, and the Single Market. The suggestion coming from the report is that the EU would need a smart industrial policy for biotech and biomanufacturing rooted in science-based policymaking, so to incentivises the scale-up of infrastructures and sustainable solutions and  to create innovative and resilient supply-chains.